New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
12:26 EDTZMHZimmer down slightly after FDA recalls PEEK Ardis Inserter
The FDA announced that it was issuing a Class I recall for Zimmer Spine's (ZMH) PEEK Ardis Inserter. A Class I recall is issued when the FDA believes that there is a reasonable probability that the use of a product could cause serious health problems. The device is used to insert Zimmer's PEEK Ardis Interbody Spacer during spinal surgery. Zimmer was told that the spacer has broken into fragments when too much lateral force is applied to the inserter in some cases, the FDA reported. As a result, patients may experience various adverse effects, including a tear in the thin covering of the spinal cord, cerebrospinal fluid leakage, significant blood loss and nerve injury, according to the agency. Long-term health risks may include disability, dysfunction, or death, it added. The FDA's recall was initiated on December 21. Zimmer, on December 20, had initiated a voluntary recall of all 315 of its PEEK inserter units. Zimmer said at that time that it had received reports of the spacer implant breaking, but did not list adverse health effects that could occur if the implant breaks. In early afternoon trading, Zimmer fell 38c, or 0.57%, to $66.35.
News For ZMH From The Last 14 Days
Check below for free stories on ZMH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent ZMH news | >>
April 24, 2014
12:10 EDTZMHZimmer advances after agreeing to merge with competitor
Subscribe for More Information
12:00 EDTZMHZimmer rises 12.6%
Zimmer is up 12.6%, or $11.51, to $102.96
10:00 EDTZMHZimmer rises 15.7%
Zimmer is up 15.7%, or $14.36, to $105.81
09:00 EDTZMHZimmer rises 17%
Subscribe for More Information
08:59 EDTZMHOn The Fly: Pre-Market Movers
Subscribe for More Information
08:43 EDTZMHZimmer deal could pressure Stryker, Smith & Nephew to grow, says Wells Fargo
Subscribe for More Information
08:41 EDTZMHZimmer: Combined company will be supported by R&D spend capability of $360M
Return on invested capital from Biomet transaction expected to exceed cost of capital by the end of the year three, with enterprise return on invested capital expected to exceed weighted average cost of capital in year one. Zimmer said it is "quite confident" the transaction will be completed in time and will be consummated in 1Q15.
08:37 EDTZMHZimmer sees Q2 EPs $1.46-$1.49, consensus $1.56
08:36 EDTZMHZimmer to suspend share repuchase program to preserve funding for transaction
Subscribe for More Information
08:35 EDTZMHZimmer sees Q2 revenue growth of 2%-3%, consensus $1.21B
Subscribe for More Information
07:54 EDTZMHSmith & Nephew up 2% after peers Zimmer, Biomet merge
Subscribe for More Information
07:49 EDTZMHZimmer backs FY14 revenue growth of 3%-5%, consensus $4.8B
Subscribe for More Information
07:13 EDTZMHZimmer cuts FY14 EPS to $6.00-$6.20 from $6.10-$6.20, consensus $6.21
Subscribe for More Information
07:11 EDTZMHZimmer reports Q1 adjusted EPS $1.50, consensus $1.47
Subscribe for More Information
07:11 EDTZMHZimmer to combine with Biomet in transaction valued at $13.35B
Subscribe for More Information
April 21, 2014
10:01 EDTZMHOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:35 EDTZMHZimmer upgraded to Buy from Hold at Cantor
Subscribe for More Information
April 15, 2014
09:23 EDTZMHBarclays medical supplies/devices analysts hold analyst/industry conference call
Subscribe for More Information
April 14, 2014
10:02 EDTZMHOn The Fly: Analyst Upgrade Summary
Acorda Therapeutics (ACOR) upgraded to Outperform from Market Perform at FBR Capital... Allegheny Technologies (ATI) upgraded to Neutral from Underperform at Sterne Agee... BP (BP) upgraded to Buy from Hold at Canaccord... Bloomin' Brands (BLMN) upgraded to Buy from Hold at Deutsche Bank... Boardwalk Pipeline (BWP) upgraded to Neutral from Underperform at BofA/Merrill... Boston Scientific (BSX) upgraded at BofA/Merrill... Charles Schwab (SCHW) upgraded to Buy from Neutral at UBS... Citigroup (C) upgraded to Hold from Sell at Rafferty Capital... Community Health (CYH) upgraded to Outperform from Perform at Oppenheimer... Eaton Vance (EV) upgraded to Neutral from Sell at Citigroup... Eli Lilly (LLY) upgraded to Hold from Underperform at Jefferies... F5 Networks (FFIV) upgraded to Buy from Hold at Stifel... HeartWare (HTWR) upgraded to Buy from Neutral at BTIG... Heartland Payment (HPY) upgraded to Hold from Sell at Stifel... Hyatt Hotels (H) upgraded to Outperform from Market Perform at FBR Capital... MasterCard (MA) upgraded to Outperform from Neutral at RW Baird... McDermott (MDR) upgraded to Neutral from Underweight at HSBC... Palo Alto (PANW) upgraded to Overweight at Stephens... PetroChina (PTR) upgraded to Neutral from Underperform at Credit Suisse... Seagate (STX) upgraded to Buy from Hold at Argus... Sensata (ST) upgraded to Buy from Neutral at Citigroup... Stryker (SYK) upgraded to Neutral from Reduce at SunTrust... TD Ameritrade (AMTD) upgraded to Buy from Neutral at UBS... TTM Technologies (TTMI) upgraded to Buy from Hold at Stifel... Transocean (RIG) upgraded to Hold from Sell at Deutsche Bank... VMware (VMW) upgraded to Outperform from Underperform at CLSA... Visa (V) upgraded to Outperform from Neutral at RW Baird... Yahoo (YHOO) upgraded to Buy from Neutral at SunTrust... Zimmer (ZMH) upgraded to Neutral from Reduce at SunTrust... bebe stores (BEBE) upgraded to Buy from Neutral at Janney Capital.
07:29 EDTZMHZimmer upgraded to Neutral from Reduce at SunTrust
SunTrust upgraded Zimmer to Neutral after its survey indicated ortho recon volumes remain strong. The firm raised its price target for shares to $93 from $83.
1 | 2 | all recent ZMH news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use